Sema4 reports that funds managed by BlackRock led its oversubscribed Series C financing of $121 million at a post-money valuation of over $1 billion.
Andrew Elbardissi, MD Partner at Deerfield Management Company, has joined Sema4’s board of directors. Sema4 has also recently added Mike Pellini, MD from Section32 (former CEO of Foundation Medicine), Rachel Sherman (former Principal Deputy Commissioner at the FDA), and Marty Chavez (former CFO of Goldman Sachs) to its board.